Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.K. advice for codeine products

This article was originally published in The Tan Sheet

Executive Summary

The U.K.'s Medicines and Healthcare products Regulatory Agency bolsters its labeling and packaging advice for manufacturers of OTC pain relief products with codeine or dihydrocodeine. In a Sept. 2 1letter to industry and pharmacists, the agency recommends warnings about overuse of the drugs be moved to the front of packaging and that codeine/DHC products be capped at 32-count size. Previous voluntary label and packaging changes for the products instituted in 2005 "have not proved effective" in reducing overuse, MHRA notes (2"The Tan Sheet" Aug. 22, 2005). The Proprietary Association of Great Britain, representing OTC manufacturers, said Sept. 3 it supports the advice recommended by MHRA's Commission on Human Medicines and its member companies already restrict codeine/DHC product packs to 32 tablets. MHRA's advice applies to U.K. OTC brands including Reckitt Benckiser's Nurofen Plus and GlaxoSmithKline's Panadol Ultra and Solpadeine Max, PAGB said

You may also be interested in...

UK Strengthens Addiction Warnings For Nonprescription Codeine Products

Warnings that long-term use of codeine and/or dihydrocodeine may lead to addiction will be added to product labeling for nonprescription analgesics that contain the ingredients, the Medicine & Healthcare products Regulatory Agency announced Aug. 15

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts